O141 The patterns of metastatic disease and survival in patients with pancreatic neuroendocrine tumours: a retrospective observational study

Abstract

Abstract Background The 5-year survival of patients with pancreatic neuroendocrine tumours (pNET) without metastatic spread can be as high as 93% and as low as 24% in cases with distant metastases, influenced by the resectability of the tumour and adjuvant therapies. This study examined the patterns of metastasis and survival outcomes of patients with pNET. Methods This retrospective observational study at a regional hepatopancreaticobiliary centre, used electronic healthcare records to identify all patients with confirmed pNET referred to the multidisciplinary team between 2010 and 2019. Demographic characteristics of the patients were compared using chi-squared testing, and the patterns of metastatic disease defined on radiological imaging. The 5-year survival outcomes were determined using Kaplan-Meier survival estimates, stratified by the presence (and location) or absence of metastatic disease. Results In total 96 [50 (52.1%) female] patients with pNET were identified. Of the female patients, 46% were older than 70-years compared with 24% of the males (p=0.016). Metastatic disease was present in 48% of patients at presentation. The commonest sites of metastases was the liver (50%) distant lymph node metastases (32%) and multisite metastases (13%). The corresponding 5-year survivals were 58%, 50% and 39%. Conclusion pNET is a unique type of pancreatic cancer with better overall survival compared with other pancreatic cancers. Survival is influenced by the patterns of metastatic disease with worse overall survival in those with multisite metastases.